Printer Friendly
The Free Library
19,607,059 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

DUSA Pharmaceuticals, Inc. Schedules Conference Call And Third Quarter 2003 Results.


Business Editors/Health/Medical Writers

WILMINGTON Wilmington.

1 City (1990 pop. 71,529), seat of New Castle co., NE Del., on the Delaware River and tributary streams, the Christina and the Brandywine; settled 1638, inc. as a city 1832.
, Mass.--(BUSINESS WIRE)--Nov. 10, 2003

DUSA DUSA Deputy Under Secretary of the Army
DUSA Deakin University Student Association
DUSA Dundee University Students' Association (Scotland)
DUSA Designated Unclassified Subject Area
 Pharmaceuticals, Inc. (NASDAQ NASDAQ
 in full National Association of Securities Dealers Automated Quotations

U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on
:DUSA) announces that its Q3 2003 corporate highlights and financial results press release will be issued on Thursday, November 13th at 7:00 a.m., to be followed by a conference call at 8:45 a.m.


          Thursday, November 13th, 2003 - 8:45 a.m. Eastern
             If calling from the US or Canada use the
                    following toll-free number:
                           800.936.4602
                          Password - DUSA

                    For International callers use
                           507.726.3331
                         Password - DUSA

            You will also be able to listen to a replay of
                        the conference call
                   using the following numbers:
                North American callers 800.334.2128
                 International callers 580.431.2723


The call will be accessible on our web site after Friday, November 14th at www.dusapharma.com.

DUSA Pharmaceuticals, Inc. is a biopharmaceutical company engaged primarily in the development of Levulan(R) Photodynamic Therapy photodynamic therapy
n.
A type of phototherapy in which a nontoxic light-sensitive compound that has been injected into a patient is exposed selectively to light, whereupon it becomes toxic to targeted malignant and other diseased cells.
 (PDT PDT
abbr.
Pacific Daylight Time


PDT Pacific Daylight Time

PDT n abbr (US) (= Pacific Daylight Time) → hora de verano del Pacífico

PDT 
) and Photodetection (PD) for multiple medical indications. PDT and PD utilize light-activated compounds such as Levulan(R) to induce in·duce
v.
1. To bring about or stimulate the occurrence of something, such as labor.

2. To initiate or increase the production of an enzyme or other protein at the level of genetic transcription.

3.
 a therapeutic or detection effect. DUSA is a world leader in topically or locally applied PDT and PD. The Company maintains offices in Wilmington, MA, Valhalla, NY, and Toronto, Ontario.
COPYRIGHT 2003 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2003, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1CANA
Date:Nov 10, 2003
Words:201
Previous Article:Integrated Business Systems & Services, Inc. Announces Results for Third Quarter 2003.
Next Article:24/7 Real Media Signs Open AdStream Central Ad Serving Agreement with Courttv.com.
Topics:



Related Articles
DUSA Pharmaceuticals, Inc. Schedules Conference Call and Second Quarter 2003 Results.
DUSA Pharmaceuticals Reports Third Quarter Corporate Highlights And Financial Results.
DUSA Announces First Quarter Levulan Kerastick End-User Sales; Positive Response at Laser Meeting.
Dusa Pharmaceuticals Reports First Quarter Corporate Highlights And Financial Results; New Canadian Distribution Agreement.
DUSA Announces Increased Second Quarter Levulan'R' Kerastick'R' and BLU-U'R' End-User Sales.
DUSA Announces Increased Third Quarter Levulan'R' Kerastick'R' End-User Sales.
DUSA Pharmaceuticals, Inc. to Host First Quarter 2005 Corporate Highlights and Financial Results Conference Call.
DUSA Pharmaceuticals, Inc. to Host Conference Call Re Second Quarter 2005 Levulan'R' Kerastick'R' and BLU-U'R' Sales Update.
DUSA Pharmaceuticals, Inc. To Host Second Quarter 2005 Corporate Highlights And Financial Results Conference Call.
DUSA Pharmaceuticals, Inc. to Host Third Quarter 2005 Corporate Highlights and Financial Results Conference Call.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles